<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_SupBiotech-Paris_Conclusion1"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu"><UL><LI class="selected"><A href="/Team:SupBiotech-Paris/Conclusion1">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:SupBiotech-Paris/Conclusion1&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Conclusion1&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Conclusion1&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:SupBiotech-Paris/Conclusion1" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:SupBiotech-Paris/Conclusion1</H1><DIV id="bodyContent"><H3 id="siteSub">From 2009.igem.org</H3><DIV id="menuhaut"><TABLE style="background-color: transparent;" cellpadding="3" cellspacing="20" align="center"><TBODY><TR><TH align="center"><A href="/Team:SupBiotech-Paris/HomeEn#drapeau" title="Team:SupBiotech-Paris/HomeEn">Home</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Team#drapeau" title="Team:SupBiotech-Paris/Team">Team</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Project_Management#drapeau" title="Team:SupBiotech-Paris/Project Management">Project Management</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Gallery#drapeau" title="Team:SupBiotech-Paris/Gallery">Gallery</A></TH><TH align="center"><A href="/Team:SupBiotech-Paris/Acknowledgement#drapeau" title="Team:SupBiotech-Paris/Acknowledgement">Acknowledgement</A></TH></TR></TBODY></TABLE></DIV><DIV id="menu" style="margin-top: 315px; background: transparent;"><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Project</DIV><P><SPAN style="color: black;"><B>Introduction</B></SPAN><A href="/Team:SupBiotech-Paris/Current_therapies#drapeau" title="Team:SupBiotech-Paris/Current therapies">Current therapies</A><A href="/Team:SupBiotech-Paris/Gene_therapies#drapeau" title="Team:SupBiotech-Paris/Gene therapies">Gene therapies</A><SPAN style="color: black;"><B>DVS</B></SPAN><A href="/Team:SupBiotech-Paris/Concept#drapeau" title="Team:SupBiotech-Paris/Concept">Concept</A><A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1">Tissue Vector</A><A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2">Cell Vector</A><A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3">Therapeutic plasmid</A><A href="/Team:SupBiotech-Paris/Conclusion1#drapeau" title="Team:SupBiotech-Paris/Conclusion1">Conclusion</A><SPAN style="color: black;"><B>Implementation</B></SPAN><A href="/Team:SupBiotech-Paris/Tissue_targeting#drapeau" title="Team:SupBiotech-Paris/Tissue targeting">Tissue targeting</A><A href="/Team:SupBiotech-Paris/Antitumor_action#drapeau" title="Team:SupBiotech-Paris/Antitumor action">Antitumor action</A><A href="/Team:SupBiotech-Paris/Treatement_modeling#drapeau" title="Team:SupBiotech-Paris/Treatement modeling">Treatment modeling</A><A href="/Team:SupBiotech-Paris/Conclusion3#drapeau" title="Team:SupBiotech-Paris/Conclusion3">Conclusion</A></P><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Ressources</DIV><P><A href="/Team:SupBiotech-Paris/Biobricks#drapeau" title="Team:SupBiotech-Paris/Biobricks">BioBricks</A><A href="/Team:SupBiotech-Paris/Material_%26_Method#drapeau" title="Team:SupBiotech-Paris/Material &amp; Method">Material &amp; Method</A><A href="/Team:SupBiotech-Paris/Bibliography#drapeau" title="Team:SupBiotech-Paris/Bibliography">Bibliography</A></P><DIV id="Partie" style="color: white; font-weight: bold; margin-bottom: -7px;">Ethics &amp; Safety</DIV><P><A href="/Team:SupBiotech-Paris/Ethic#drapeau" title="Team:SupBiotech-Paris/Ethic">Ethics</A><A href="/Team:SupBiotech-Paris/Safety#drapeau" title="Team:SupBiotech-Paris/Safety">Safety</A></P></DIV><H1><SPAN class="mw-headline" id="Conclusion"> Conclusion </SPAN></H1><P>Vectorization encounters several problematic like stability, toxicity, targeting, resistance or stealth to the immune system, passage through the membrane and industrialization. 
The <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">Double Vector System (DVS</A>) offers a key to these major problematic. <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> is composed by a <A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1">first vector</A>, tissue vector, from bacterial type, able to reach a tissue and by a <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2"> second vector</A>, from phage type, able to reach a target cell. When the target cell is reached, it releases a <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3"> therapeutic plasmid</A> which has an action against the disease.</P><P>
The <A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1">first vector</A> : <I>Mycobacterium avium</I>, goes to the tissue of interest for which it has a high affinity. It resists to the immune system thanks to its cell wall and has a low toxicity for its host. In the target tissue, it creates the <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2"> second vector</A>, the cell vector. 
The <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2">cell vector</A> targets the cell type of interest, which increase the DVS specificity. The <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2">cell vector</A> integer itself in target cell, thanks to viral proteins exposed to its capsid. These proteins permit it to be efficient and offer the capacity to pass through eukaryotic cell membrane. The <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2"> cell vector</A> is able to encapsidate the <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3"> therapeutic plasmid</A> and to deliver it after its own internalization. 
The <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3"> therapeutic plasmid</A> expresses one or more therapeutic genes replying to target physiopathology. It possesses a sequence providing its encapsidation in the <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2">cell vector</A>, and a DTS sequence  (DNA nuclear targeting sequence) to its transport inside target cell nucleus. </P><P><A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> improves underlying vectorization problematic. <A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1"> Tissue vector</A> characteristics bring a solution to specificity issue and to elimination by the immune system met by vectors. <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2"> Cell vector</A> characteristics reinforce the vector specificity and give a solution to <A href="/Team:SupBiotech-Paris/Concept#drapeau" title="Team:SupBiotech-Paris/Concept">pass through the cell membrane</A> and to the therapeutic agent delivery.<A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> becomes one of the more specific vectors by permitting the transport of one or more gene insert in a therapeutic goal with a high efficiency.</P><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Conclusion1#drapeau" title="Team:SupBiotech-Paris/Conclusion1">Back to top</A></SPAN></P><H2><SPAN class="mw-headline" id="DVS_application"> DVS application </SPAN></H2><P>Gene therapy actually permits to treat several pathologies. <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> is a new tool to integer a gene insert in a target cell. We choose to use <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> in lung cancer. 
Nowadays, lung cancer is the most spread cancer. Often associated to tobacco, it can touch people who had never smoked as well. </P><P>
Lung cancer can be divided into several types : </P><DIV style="margin-left: 100px;"><P>-	Squamous cell carcinoma (35-40 %) 
-	Adenocarcinoma (25-35 %) 
-	Large cell carcinoma (10-15 %) 
-	Small cell carcinoma (20-25 %) </P></DIV><P>In each case, like in most cancers, tumor suppressor genes are mutated and become non functional. <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> bring tumor suppressor genes « wild type » and their promoter in cancer cell of the lung. 
Lung cancer has been chosen in consequence of the natural tropism of the <A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1">tissue vector</A>, Mycobacterium <I>avium</I>, for lung. Inside the lung, it delivers the <A href="/Team:SupBiotech-Paris/Concept2#drapeau" title="Team:SupBiotech-Paris/Concept2">cell vector</A>. These one infects cells. In the case of healthy cells, tumor suppressor gene promoters are naturally present but not activated. <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3"> Therapeutic plasmid</A> promoters will not be activated as well, so there is not apoptosis induction. But in the case of tumor cells, tumor suppressor gene promoters are activated but their sequence are mutated so proteins are not functional and the apoptotic pathway is not induced. <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3">Therapeutic plasmid</A> brings a new sequence  of these tumor suppressor genes with their promoters. These promoters are activated and new transcript proteins are functional and able to induce the apoptotic pathway of the cell.</P><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Conclusion1#drapeau" title="Team:SupBiotech-Paris/Conclusion1">Back to top</A></SPAN></P><H2><SPAN class="mw-headline" id="Future_prospects"> Future prospects </SPAN></H2><P><A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> is a tool usable in several diseases. It can be adapted to pathologies by the strategic choice of the <A href="/Team:SupBiotech-Paris/Concept1#drapeau" title="Team:SupBiotech-Paris/Concept1">tissue vector</A>. In function of the tropism of the bacterial strain chosen, different organs are reached. Furthermore, <A href="/Team:SupBiotech-Paris/Concept#DVS" title="Team:SupBiotech-Paris/Concept">DVS</A> is specific thanks to the <A href="/Team:SupBiotech-Paris/Concept3#drapeau" title="Team:SupBiotech-Paris/Concept3"> therapeutic plasmid</A> which contains interchangeable genetic sequences depending of the target disease. </P><P><SPAN style="float: right"><A href="/Team:SupBiotech-Paris/Conclusion1#drapeau" title="Team:SupBiotech-Paris/Conclusion1">Back to top</A></SPAN></P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2009.igem.org/Team:SupBiotech-Paris/Conclusion1">http://2009.igem.org/Team:SupBiotech-Paris/Conclusion1</A>&quot;</DIV></DIV></DIV><DIV id="footer-box"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:SupBiotech-Paris/Conclusion1" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:SupBiotech-Paris/Conclusion1" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Conclusion1&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:SupBiotech-Paris/Conclusion1&amp;oldid=137619" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2009.igem.org:Privacy_policy" title="2009.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2009.igem.org:General_disclaimer" title="2009.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>